| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Cyproheptadine HCl hydrate is a hydrochloride salt form of cyproheptadine which is a histamine receptor antagonist. Furthermore, cyproheptadine functions as an antimuscarinic and serotonin reagent. Pituitary-dependent Cushing's syndrome, anorexia, migraine, pruritic dermatoses, and postgastrectomy-dumping syndrome are among the conditions it is used to treat. Cyproheptadine, a 5-HT2A receptor antagonist, has been shown to counteract serotonin-induced platelet aggregation caused by ADP both in vitro and in vivo, indicating that it has antiplatelet and thromboprotective properties.
| Targets |
5-HT2 Receptor
|
|---|---|
| References |
| Molecular Formula |
C21H21N.HCL.1.5H2O
|
|---|---|
| Molecular Weight |
350.0
|
| Exact Mass |
287.17
|
| Elemental Analysis |
C, 71.88; H, 7.18; Cl, 10.10; N, 3.99; O, 6.84
|
| CAS # |
41354-29-4
|
| Related CAS # |
Cyproheptadine hydrochloride; 969-33-5
|
| Appearance |
Solid powder
|
| SMILES |
CN1CC/C(CC1)=C2C3=CC=CC=C3C=C(C=CC=C4)C4=C/2.[H]O[H].[H]Cl
|
| InChi Key |
OERTXEVZEWASFH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H21N.ClH.H2O/c1-22-12-10-16(11-13-22)21-15-18-7-3-2-6-17(18)14-19-8-4-5-9-20(19)21;;/h2-9,14-15H,10-13H2,1H3;1H;1H2
|
| Chemical Name |
4-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)-1-methylpiperidine hydrochloride sesquihydrate
|
| Synonyms |
Periactin; Eiproheptadine; Cyproheptadine Hydrochloride; Sesquihydrate; Periactinol; Dronactin; Ciproheptadina; Peritol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~33.3 mg/mL (~95 mM)
H2O: ~0.67 mg/mL (~1.9 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8571 mL | 14.2857 mL | 28.5714 mL | |
| 5 mM | 0.5714 mL | 2.8571 mL | 5.7143 mL | |
| 10 mM | 0.2857 mL | 1.4286 mL | 2.8571 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02418949 | Active Recruiting |
Drug: Placebo for Cyproheptadine Drug: Cyproheptadine |
Stroke Hemiparesis Muscle Spasticity |
Shirley Ryan AbilityLab | November 2015 | Not Applicable |
| NCT06175273 | Not yet recruiting | Drug: Cyproheptadine Drug: Dronabinol Other: Standard of Care |
Pediatric Cancer Muscle Loss Malnutrition, Child |
Corey Hawes | January 2024 | Phase 2 Phase 3 |
| NCT05469165 | Recruiting | Drug: Cyproheptadine 4 Mg Oral Tablet Other: Placebo |
Ischemic Mitral Regurgitation | Laval University | June 20, 2023 | Phase 2 |
| NCT06147622 | Not yet recruiting | Drug: Prazosin + cyproheptadine Drug: KT110 |
Alcohol Use Disorder | Kinnov Therapeutics | February 2024 | Phase 1 |
| NCT00066248 | Completed | Drug: cyproheptadine hydrochloride Drug: megestrol acetate |
Brain Tumor Cachexia Leukemia Lymphoma |
University of South Florida | June 2003 | Phase 2 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
